

Company Profile

RTO: Feb. 2019

Location: Colombia, Argentina, Canada

Employees: 60+

Industry: Medical cannabis extraction

Catalyst: Large scale producer of naturally grown premium quality cannabis and leading international supplier of processed, and standardized medicinal-grade cannabis oil extracts and related products

Leadership

Christian Toro, *Executive Chairman*
CEO & founder of various firms, political consultant, university professor

Dr. Patricio Stocker, *CEO*
Former CEO & Director of PharmaCielo;
25+ years of international executive experience

Camilo Villalba, *COO & Co-Founder*
Entrepreneur & corporate strategist;
expert in business development

Ian D. Atacan, CPA, CMA, CFO
Former CFO of cannabis cultivator
acquired by Tilray

Eduardo Molinari, *CMO*
Former CEO of Abbvie LA-North; expert
in R&D in the pharmaceutical industry

Contact

Jessika Angarita, Pacta Relations
angarita@pactarelations.com
Tel: +1 (305) 877 4710

Dr. Patricio Stocker, Chief Executive Officer
pstocker@blueberriesmed.com
Tel: +57 (320) 333 6912

Camilo Villalba, Chief Operating Officer
cvillalba@blueberriesmed.com
Tel: +57 (313) 483 0131

Ian D. Atacan, Chief Financial Officer
iatacan@blueberriesmed.com
Tel: +1 (416) 562 3220

Currency

Unless otherwise indicated, all dollar (“\$”) values herein are in United States dollars.

Investment Highlights

- A leading Latin American producer of premium medical-grade cannabis products with operations in Colombia and Argentina
- Highly experienced team with extensive global strategic relations
- Industry leading operational costs thanks to ideal climate and efficient labor force
- Large cultivation footprint with scalable growing capacity through contract growers
- 142 exclusive Colombian cannabis strains with high CBD and THC contents
- Strong global partnerships for product development and distribution
- Strategic extraction and processing model in Free Trade Zone

Large Scalable Operations

- Structural cost advantage due to ideal growing and climate conditions.




Strategic Partnerships



Strategic Overview



Colombia Operations - Heartland of Blueberries



Q4 2019 - 1H 2020 Catalysts

- Approval of Cultivars
- First Commercial Crop in Colombia
- Pilot Cultivation in Argentina
- First Commercial Extraction & Sales Start
- GMP Certification Process

Unique Opportunity

- Highly experienced team with expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing
- Strong local operating experience and partnerships with deep global strategic relations
- Ideally located Colombian operations with opportunity to scale through owned and contracted capacity
- One of three companies with full rights to cultivate, extract, sell and export cannabis in Argentina through joint venture with state-owned company.
- Undervalued in relation to industry peers.

Disclaimers

This presentation has been prepared by Blueberries Medical Corp. ("the Company" or "Blueberries"). Certain information in this presentation and the material contained herein are confidential and are not to be disclosed to the public. This presentation is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities of the Company in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation. Readers of this presentation should pay particular attention to the information under the heading "Cautionary Note Regarding Forward-Looking Information".

By their acceptance of this presentation, recipients agree that they will not transmit, reproduce or make available to any person this presentation or any of the information contained herein. Some information in this presentation describes the Company's business plans, only including certain assets and relationships held and timing of future events (for example, commencement of operations and the execution dates of material partnership and commercial agreements for the international distribution of the Company's products).

Cautionary Note Regarding Forward-Looking Information

Certain information set forth in this presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian and United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which includes but is not limited to statements related to activities, events or developments that the Company expects or anticipates will or may occur in the future, statements related to the Company's business strategy, objectives and goals, and management's assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements are often identified by the use of words such as "may", "will", "could", "would", "anticipate", "believe", "expect", "intend", "potential", "estimate", "budget", "scheduled", "plans", "planned", "forecasts", "goals" and similar expressions. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In this presentation, forward-looking statements relate to, among other things, the Company's strategies and objectives, future expansion plans under consideration, entering into proposed commercial agreements to develop and advance the Company's business interests, the estimated cost of production for the Company's products, the expected value of the global medicinal cannabis market, market growth and size, future revenues, targeted EBITDA and profits, proposed use of the Company's funds, ability to scale the Company's production model, execution of distribution strategy and forecasts of the number of product lines and sales. No statement in this presentation is intended to be nor may be construed as a profit forecast. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not undertake any obligations to revise or update any forward-looking statements, except as required by applicable securities law.

Cautionary Note Regarding Future-Oriented Financial Information

To the extent any forward-looking information in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Note Regarding Forward Looking Information". The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual financial position or results of operations.

Financial Measures

There are measures included in this presentation that do not have a standardized meaning under generally accepted accounting principles (GAAP) and therefore may not be comparable to similarly titled measures and metrics presented by other publicly traded companies. The company includes these measures because it believes certain investors use these measures and metrics as a means of assessing financial performance. EBITDA (earnings before interest, taxes, depreciation and amortization is calculated as net earnings before finance costs (net of finance income), income tax expense, and depreciation and amortization of intangibles) is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

Fully Licensed

Cultivation | Processing | Extraction | Export

\$0.15 Production Cost
(per gram of flower)

142 Exclusive
Strains



Contact

Jessica Angarita, Pacta Relations
angarita@pactarelations.com
Tel: +1 (305) 877 4710

Dr. Patricio Stocker, Chief Executive Officer
pstocker@blueberriesmed.com
Tel: +57 (320) 333 6912

Camilo Villalba, Chief Operating Officer
cvillalba@blueberriesmed.com
Tel: +57 (313) 483 0131

Ian D. Atacan, Chief Financial Officer
jatacan@blueberriesmed.com
Tel: +1 (416) 562 3220